Bifidobacterium breve B632™ (DSM 24706)
Cardiometabolic Health
Lipid Metabolism
Supports healthy cholesterol metabolism [in vitro]
Blend
Finished dosage form
a) De Prisco A. et al. An interesting Mechanism of Cholesterol Reduction by Probiotic Strains. Poster from the 15th International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health – IPC2022, held in Bratislava on 27-30 June 2022
Internal data on CLA production available upon request
For information on blends containing B632™, see the following Blends and Products pages:
- BIFIASTHM®
- BIFISLIM® Junior
- BIFIBABY®
- CELIAFLORA™ JUNIOR
- B632 + BR03™ + LDD01
Oral Care
Oral microbiome
Anti-pathogenic activity against oral pathogens [in vitro]
Blend
Finished dosage form
a) Zanetta P, et al. Selection of Probiotic Strains for Oral Health. Poster from the XIX CONGRESSO NAZIONALE CSID, held in Novara on 1-2 October, 2022
For information on blends containing B632™, see the Blends and Products pages listed above.
Gastroenterology
Gut Microbiome
Inhibits pathogenic E. coli and other Enterobacteriaceae [in vitro]
Single Strain
Blend
Finished dosage form
a) Mogna L. et al. Assessment of the in vitro inhibitory activity of specific probiotic bacteria against different Escherichia coli strains. J Clin Gastroenterol. 2012; 46 Suppl:S29-32. doi:10.1097/MCG.0b013e31826852b7
b) Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053
For information on blends containing B632™, see the Blends and Products pages listed above.
Pediatrics
Infant GI Health
Inhibits pathogenic E. coli [in vitro]
Inhibits Enterobacteriaceae, and other coliforms isolated from colicky infants [in vitro]
Supports the function of gut epithelial cells [in vitro]
Blend
Finished Dosage Form
a) Aloisio I. et al. Characterization of Bifidobacterium spp. strains for the treatment of enteric disorders in newborns. Appl Microbiol Biotechnol 2012, 96:1561–1576. Doi: 10.1007/s00253-012-4138-5
b) Simone M. et al. The probiotic Bifidobacterium breve B632 inhibited the growth of Enterobacteriaceae within colicky infant microbiota cultures. Biomed Res Int. 2014;2014:301053. doi: 10.1155/2014/301053.
c) Mogna L. et al. Assessment of the In Vitro Inhibitory Activity of Specific Probiotic Bacteria Against Different Escherichia coli strains. J. Clin. Gastroenterol. 2012;46 Suppl.S29-32. Doi: 10.1097/MCG.0b013e31826852b7
For information on blends containing B632™, see the Blends and Products pages listed above.
